Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients
|
|
- Tracey Daniel
- 5 years ago
- Views:
Transcription
1 Blackwell Science, LtdOxford, UKJGHJournal of Gastroenterology and Hepatology Blackwell Publishing Asia Pty Ltd Original ArticleLow-dose rabeprazole-based triple therapywm Wong et al. Journal of Gastroenterology and Hepatology (2005) 20, DOI: /j x GASTROENTEROLOGY Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients WAI MAN WONG, JIAQING HUANG, HARRY HX XIA, FIONA MY FUNG, TERESA SM TONG, KESS L CHEUNG, VICKY YK HO, KAM CHUEN LAI, CHI KUEN CHAN, ANNIE OO CHAN, CHEE-KIN HUI, SHIU KUM LAM AND BENJAMIN CY WONG Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong Abstract Background: Rabeprazole in combination with amoxicillin and metronidazole (RAM) has been shown to be an effective second-line treatment of Helicobacter pylori infection. The effects were compared of 7-day low-dose and high dose rabeprazole in RAM for the primary treatment of H. pylori infection in Chinese patients. Methods: Helicobacter pylori-positive dyspeptic patients were randomized to receive either (i) rabeprazole 10 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM-10) or (ii) high-dose rabeprazole 20 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM-20), each given twice daily for 7 days. Helicobacter pylori eradication was confirmed by 13 C-urea breath test 5 weeks after stopping medications. Side-effects of treatments were documented. Results: A total of 120 patients were eligible for analysis. By intention-to-treat and per-protocol analysis, the eradication rates were 83% and 86% in the RAM-10 group and 75% and 76% in the RAM-20 group, respectively (P = 0.26 and P = 0.17). Both regimens were well-tolerated and compliance was >98% in both groups. Conclusions: Low-dose rabeprazole in combination with amoxicillin and metronidazole is an effective, economical and well-tolerated therapy for the treatment of H. pylori infection in Chinese population Blackwell Publishing Asia Pty Ltd Key words: amoxicillin, eradication, Helicobacter pylori, metronidazole, rabeprazole. INTRODUCTION It is accepted that Helicobacter pylori is one of the major causes of dyspepsia, peptic ulcer and gastric cancer. 1,2 Eradication of H. pylori significantly reduces the relapse of peptic ulcers and may possibly reduce the incidence of gastric cancer. 3 5 In the Asia Pacific Consensus conference on the management of H. pylori infection, the recommended regimens include the use of proton pump inhibitor (PPI)/ranitidine bismuth citrate in standard dose plus two antibiotics consisting of clarithromycin plus either amoxicillin or metronidazole, each given twice daily for 7 days. 1 Bacterial resistance to metronidazole or clarithromycin is an important factor leading to treatment failure. 6 Primary resistance to metronidazole and clarithromycin is common in Hong Kong and significantly affects the effectiveness of the standard triple therapies recommended by the Asia Pacific consensus conference. 1,7,8 The problem is compounded by the cost of these eradication regimens because clarithromycin is an expensive antibiotic. Non-clarithromycin-based triple therapies using a PPI plus amoxicillin and metronidazole have been shown to be an effective and economical treatment for H. pylori infection in Asian countries. 9,10 Rabeprazole is a benzimidazole PPI with a rapid onset of action In vitro studies have demonstrated that rabeprazole has a more potent antibacterial activity against H. pylori when compared with either omeprazole or lansoprazole Reports from Japan have demonstrated that rabeprazole in combination with amoxicillin and metronidazole is an effective secondline treatment of H. pylori infection after failure of PPI, amoxicillin and clarithromycin regimen. 18,19 However, Correspondence: Dr Benjamin CY Wong, Department of Medicine, University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong. bcywong@hku.hk Accepted for publication 1 August 2004.
2 936 WM Wong et al. rabeprazole in combination with amoxicillin and metronidazole as a primary treatment of Helicobacter pylori infection has been inadequately studied. 20 A systematic review of the efficacy of rabeprazole-based therapies in H. pylori eradication has demonstrated that low-dose rabeprazole (20 mg/day) in combination with amoxicillin and clarithromycin was equally effective as the highdose rabeprazole regimens for H. pylori eradication. 21 Thus the aims of the present study were (i) to perform a head-to-head comparison of 1-week low-dose (20 mg/day) rabeprazole, amoxicillin and metronidazole triple therapy versus 1-week high-dose (40 mg/day) rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of H. pylori infection in Chinese patients; and (ii) to determine the clinical response and safety profile of the two regimens. METHODS Patient characteristics Patients with newly diagnosed H. pylori infection with either active duodenal ulcer (DU) >5 mm in size, or non-ulcer dyspepsia (NUD) were recruited from the endoscopic unit of the Department of Medicine, Queen Mary Hospital, Hong Kong. Dyspepsia was defined as persistent or recurrent upper abdominal pain or discomfort over the preceding 3-month period in accordance with the Rome criteria for dyspepsia. 22 Patients were excluded if (i) they were under 18 or over 80 years of age; (ii) gastric ulcer was found on endoscopy; (iii) H 2 -receptor antagonists, PPI, bismuth compounds and/ or antibiotics and/or regular intake of NSAIDs were used within the 4 weeks prior to study entry; (iv) had active ulcer bleeding, previous gastric or duodenal surgery; (v) had history of allergy to the study medications; or (vi) had significant concomitant medical diseases. The study was approved by the local Institutional Review Board (IRB) and written informed consent was obtained from all patients before the beginning of the study. We followed the recommendation of the Consolidated Standards of Reporting Trials (CONSORT) trial guidelines for reporting the results. 23 During endoscopy, two antral biopsies and one corpus biopsy were taken. One antral biopsy was used for rapid urease test (RUT) and the rest were sent for histological examination of H. pylori status by hematoxylin and eosin stains and Giemsa stain. Specimens were read by experienced pathologists who were blinded to all clinical information, including the RUT results. The H. pylori infection was defined as positivity of both tests. Equivocal cases were excluded from the study. This approach has been validated at Queen Mary Hospital before with an accuracy of 100%. 24 Treatment regimens Patients were then randomized into either 1-week of rabeprazole 10 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM-10), each given twice daily for 7 days; or 1 week of rabeprazole 20 mg, amoxicillin 1000 mg and metronidazole 400 mg (RAM-20), each given twice daily for 7 days. Randomization was performed by drawing a sequentially numbered sealed envelope that contained a preassigned computer-generated randomized treatment. Patients were given antacids whenever necessary. The patients were given a diary in which they recorded any side-effects and symptoms during treatment period. Side-effects were also documented by a direct questioning approach during scheduled visits at day 14 in addition to self-reporting. Eradication was determined by a validated 13 C-urea breath test ( 13 C-UBT) 5 weeks after the end of treatment. 25 This protocol has been validated at Queen Mary Hospital with a sensitivity and specificity of 96.5% and 97.7%, respectively. Briefly, patients were fasted 4 h before the test. No test meal was given and a pre-dose breath sample was obtained. The patients were asked to drink 75 mg 13 C-urea powder dissolved in 50 ml of water. The second breath sample was collected at 30 min after the administration of the 13 C-urea drink. The cut-off value used for determining the test result was 5. All patients were kept in a sitting position over the whole testing period. The collected samples were analyzed by the purpose-built isotope ratio mass spectrometer. Clinical response Symptoms such as daytime epigastric pain, nocturnal abdominal pain, bloating or post-prandial fullness, belching, acid reflux and heartburn were assessed by the investigators. 26 All symptoms were rated as absent, mild (transient and easily tolerated), moderate (discomfort and affecting normal activities) and severe (incapacitating symptoms with inability to perform daily activities). The clinical response of each subject was assessed at the follow-up visit by a gastroenterologist who was blinded to the H. pylori status of the patient. Symptom response was defined as complete resolution of pretreatment symptoms. Symptom improvement was defined as shifting from severe to moderate or from mild or moderate to mild following the treatment. If all symptoms were resolved, the patient was classified as cure. Symptom improvement was assigned when some pretreatment symptoms were improved, while a failure was assigned when there was no improvement. If a patient was asymptomatic before treatment or if the patients were not assessed, an indeterminate status was assigned. Statistical analysis The intention-to-treat analysis principle was applied, which included all patients who had taken at least one tablet of the study drugs. In the per-protocol analysis, patients with poor drug compliance (<75% intake of study drugs) and defaulters were excluded from the analysis. The c 2 and student s t-tests were used for statistical analyses. All analyzes were performed using SPSS
3 Low-dose rabeprazole-based triple therapy 937 version 11.0 (SPSS, Chicago, IL, USA). In view of the high prevalence of metronidazole-resistant H. pylori strains in Hong Kong, an expected efficacy of 60% successful eradication was adopted. To detect a 25% difference in efficacy of the tested regimens with a power of 80% and a at 5%, at least 57 patients in each arm were required. RESULTS A total of 120 patients were recruited from June 2003 to November Sixty patients were randomized to receive RAM-10 and 60 patients to receive RAM-20 (Fig. 1). Three patients were excluded from the perprotocol analysis (two patients were non-compliant to the protocol and one patient refused follow up). The baseline characteristics of the patients and their respective diagnosis are listed in Table 1. The mean age of these patients was 49 years (range years). There were 53 men (mean age 54 years) and 67 women (mean age 45 years). Overall the distribution of endoscopic diagnoses was similar between the two groups, although more patients with DU were in the RAM-20 group compared to the RAM-10 group (20% vs 7%, P = 0.06). Helicobacter pylori eradication The results of H. pylori eradication are listed in Table 2. By intention-to-treat analysis, the eradication rates in RAM-10 and RAM-20 groups were 83% (50/60) and 75% (45/60), respectively (P = 0.26). By per-protocol analysis, the eradication rate in the RAM-10 group was 86% (50/58) and in the RAM-20 group was 76% (45/ 59) (P = 0.17). There was no statistical difference in H. pylori eradication rates between the two groups in both analyses. The combined eradication rate in patients with DU, gastroduodenal erosions and NUD were 69%, 90% and 80%, respectively (P = 0.41). Clinical response *RAM-10 (n=60) Total eligible patients for randomization (n=120) *RAM-20 (n=60) The three most common symptoms reported by the patients at the baseline visit were belching (74%), bloating or post-prandial fullness (57%) and epigastric pain (57%). In terms of symptom response, there was no difference in the proportion of patients with cure, improvement, or failure between the two treatment groups (Table 2). Noncompliance Defaulted Completed (n=58) N=1 N=1 Figure 1 CONSORT flowchart of the study patients. RAM- 10, rabeprazole 10 mg b.i.d., amoxicillin 1000 mg b.i.d., metronidazole 400 mg b.i.d. for 7 days. RAM-20, rabeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d., metronidazole 400 mg b.i.d. for 7 days. N=1 N=0 Completed (n=59) Side-effects Drug compliance was excellent. Ninety-eight percent (59/60) of the patients in the RAM-10 group and 97% (58/60) of the patients in the RAM-20 group completed the study medications. There was no hospitalization or mortality during the study period. The most common side-effects were increase in stool frequency/loose stool, dizziness, malaise and nausea. The total proportion of Table 1 Study patients RAM-10 RAM-20 Table 2 Helicobacter pylori eradication rates RAM-10 RAM-20 P No. patients (intention-to-treat) Age (years), mean (range) 51 (18 80) 47 (18 77) Male/female 25/35 28/32 Diagnosis DU 4 12 Gastroduodenal erosions 7 3 NUD DU, duodenal ulcer; NUD, non-ulcer dyspepsia; RAM-10, rabeprazole 10 mg b.i.d., amoxicillin 1000 mg b.i.d., metronidazole 400 mg b.i.d. for 7 days, RAM-20, rabeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d., metronidazole 400 mg b.i.d. for 7 days. Eradication Intention-to-treat 50/60 (83) 45/60 (75) Per-protocol analysis 50/58 (86) 45/59 (76) Clinical response Cure 13 (22) 21 (35) Improvement 30 (50) 27 (45) Failure 16 (27) 7 (12) Indeterminate 1 (2) 5 (8) RAM-10, rabeprazole 10 mg b.i.d., amoxicillin 1000 mg b.i.d., metronidazole 400 mg b.i.d. for 7 days, RAM-20, rabeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d., metronidazole 400 mg b.i.d. for 7 days.
4 938 WM Wong et al. Table 3 Side-effects patients with side-effects during treatment was similar between the two groups (P = 0.28; Table 3). DISCUSSION RAM-10 RAM-20 Increase stool frequency/ 6 (10) 10 (17) loose stool Dizziness 5 (8) 6 (10) Nausea 1 (2) 2 (3) Malaise 1 (2) 3 (5) Others 5 (8) 4 (7) 1.0 Total episodes Total patients (%) 15 (25) 20 (33) RAM-10, rabeprazole 10 mg b.i.d., amoxicillin 1000 mg b.i.d., metronidazole 400 mg b.i.d. for 7 days; RAM-20, rabeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d., metronidazole 400 mg b.i.d. for 7 days. Other side-effects: taste disturbance, headache, anorexia and miscellaneous side-effects. We reported a randomized study with head-to-head comparison of 7-day low-dose rabeprazole (20 mg/day), amoxicillin and metronidazole (RAM-10) triple therapy versus 7-day high-dose rabeprazole (40 mg/day), amoxicillin and metronidazole (RAM-20) triple therapy for the eradication of H. pylori infection, which has a H. pylori metronidazole resistance rate of 38 49%. 7,8 The H. pylori eradication rates were similar between the two treatment groups (RAM-10 and RAM-20) by intention-to-treat (83% vs 75%) or per-protocol (86% vs 76%) analysis, respectively. To the best of our knowledge, this is the first prospective randomized study to compare the efficacy of lowdose rabeprazole amoxicillin metronidazole with highdose rabeprazole amoxicillin metronidazole for treating H. pylori infection. The only report of rabeprazole amoxicillin metronidazole regimen as a primary treatment of H. pylori infection was a 4-arm study with 19 patients in the RAM group and the dosage of rabeprazole used was 40 mg/day. 20 In that study, the intentionto-treat eradication rate was 89% in the RAM-20 group. However, RAM is commonly used as a second-line treatment regimen for patients with treatment failures. 18,19 Murakami et al. reported an open-label study of 1-week high-dose rabeprazole (20 mg b.i.d.), amoxicillin (750 mg b.i.d.) and metronidazole (250 mg b.i.d.) for the treatment of 92 patients who failed firstline H. pylori treatment consisting of a PPI, amoxicillin and clarithromycin. 18 The intention-to-treat eradication rate was 88% overall and the eradication rate for metronidazole-resistant strains was 82%. In another study, Isomoto et al. performed a head-to-head comparison of 2-week rabeprazole (20 mg b.i.d.) and amoxicillin (1000 mg b.i.d.) and 1-week rabeprazole (10 mg b.i.d.), P amoxicillin (750 mg b.i.d.) and metronidazole (250 mg b.i.d.) in 123 patients who failed first-line H. pylori treatment. 19 Antibiotics resistance pattern and cytochrome p450 (CYP)2C19 genotype were studied. The intention-to-treat eradication of the rabeprazole amoxicillin combination was 59%, while the eradication for the rabeprazole amoxicillin metronidazole combination was 82% (P < 0.01). The CYP2C19 genotypes and metronidazole resistance did not influence the treatment outcome. They concluded that low-dose rabeprazole, amoxicillin, metronidazole regimen is an effective second-line treatment of H. pylori infection in Japan. The reasons for the efficacy of the low-dose regimen are believed to be due to a faster onset of antisecretory action Furthermore, the metabolism of rabeprazole is less dependent on the CYP2C19 system and therefore allows higher drug concentration, which may contribute to a higher eradication rate even in subjects with extensive metabolizer genotype. 27 It has been shown by the MACH2 study that in vitro metronidazole resistance could be partially overcome by the use of PPI; in that study H. pylori eradication with metronidazole clarithromycin combination treatment was 43%, but increased to 76% when omeprazole was added. 28 This may explain the satisfactory H. pylori eradication rate despite the presence of metronidazole resistance in the two Japanese studies. 18,19 Clarithromycin is an expensive antibiotic. In view of the current health and economic environment, the establishment of a cheap, well-tolerated and effective therapy is more sensible for developing countries, where a high prevalence of H. pylori infection usually exists. Unfortunately, antibiotics sensitivity was not performed in the current study. However, it is reasonable to assume that the metronidazole resistance rate should not differ greatly from our previous cohorts. 7,8 Further comparative studies with antibiotic sensitivity data are warranted in this aspect. The intention-to-treat eradication rates of RAM-10 and RAM-20 obtained in the present study were comparable to those achieved with rabeprazole amoxicillin clarithromycin reported in a recent meta-analysis of rabeprazole-based therapies for H. pylori eradication. 21 In that meta-analysis, 7-day rabeprazole amoxicillin clarithromycin had a mean eradication rate of 78%. Interestingly, when low-dose rabeprazole (20 mg/day) and high-dose rabeprazole (40 mg/day) regimens were analyzed separately, the low-dose rabeprazole regimen had a mean eradication rate of 81%, while the high-dose rabeprazole regimen had a mean eradication rate of 75%, suggesting that the low-dose regimen is at least as effective as the high-dose regimen. However, a direct head-to head comparative study will be needed to confirm the aforementioned observation. A recent Asian study using low-dose rabeprazole amoxicillin clarithromycin combination also reported a satisfactory intention-to-treat eradication rate of 82%. 29 Furthermore, the low-dose rabeprazole regimen has a satisfactory ulcer healing rate and side-effects profile. Both regimens were well tolerated and side-effects were present in 25% of the RAM-10 group and 33% of the RAM-20 group. The most common side-effects were increase in stool frequency/loose stool, dizziness
5 Low-dose rabeprazole-based triple therapy 939 and malaise. In general, both regimens were well tolerated by the patients and compliance was 98% in both groups. Thus the low-dose rabeprazole amoxicillin metronidazole regimen appears to be an economical treatment according to the results of the present study. In conclusion, this head-to-head comparison study showed similar H. pylori eradication rates between lowdose rabeprazole amoxicillin metronidazole regimen and the high-dose rabeprazole amoxicillin metronidazole regimen. Both regimens were well-tolerated. Lowdose rabeprazole amoxicillin metronidazole based triple therapy is an effective and economical treatment of H. pylori infection in Chinese population. ACKNOWLEDGMENTS The authors would like to thank nurse specialist M Chong and endoscopy nurses KW Wong, VSY Tang, DKK Chang and WP Yung for assistance. The present study was supported by the Simon KY Lee Gastroenterology Research Fund and Gastroenterological Research Fund, University of Hong Kong. WMW is an RGC clinical research fellow and is supported by the Competitive Earmarked Research Grant HKU 7487/03 M of the Hong Kong Research Grant Council, Hong Kong. REFERENCES 1 Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J. Gastroenterol. Hepatol. 1998; 13: Wong BCY, Lam SK, Wong WM et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: Rauws EA, Tytgat GNJ. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990; 335: Marshall BJ, Goodwin CS, Warren JR et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; 2: Wong BCY, Lam SK, Lai KC et al. Triple therapy for Helicobacter pylori eradication is more effective than longterm maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective longterm follow-up study. Aliment. Pharmacol. Ther. 1999; 13: Houben MH, Van de Beek D, Hensen EF et al. A systematic review of Helicobacter pylori eradication therapy: the impact of antimicrobial resistance on eradication rates. Aliment. Pharmacol. Ther. 1999; 13: Wong WM, Gu Q, Wang WH et al. Effects of primary metronidazole and clarithromycin resistance to Helicobacter pylori on omeprazole, metronidazole, and clarithromycin triple-therapy regimen in a region with high rates of metronidazole resistance. Clin. Infect. Dis. 2003; 37: Wang WH, Wong BCY, Mukhopadhyay AK et al. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment. Pharmacol. Ther. 2000; 14: Wong BCY, Xiao SD, Hu FL et al. Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomised placebo controlled study. Aliment. Pharmacol. Ther. 2000; 14: Hung WK, Wong WM, Wong GS et al. One-week ranitidine bismuth citrate, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese. Aliment. Pharmacol. Ther. 2002; 16: Williams MP, Pounder RE. The pharmacology of rabeprazole. Aliment. Pharmacol. Ther. 1999; 13 (Suppl. 3): Stedman CA, Barclay ML. Comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment. Pharmacol. Ther. 2000; 14: Carswell CI, Goa KL. Rabeprazole: an update of its use in acid-related disorders. Drugs 2001; 61: Hirai M, Azuma T, Ito S, Kato T, Kohli Y. A proton pump inhibitor, E3810, has antibacterial activity through binding to Helicobacter pylori. J. Gastroenterol. 1995; 30: Kawakami Y, Akahane T, Yamaguchi M et al. In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob. Agents Chemother. 2000; 44: Tsutsui N, Taneike I, Ohara T et al. A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the motility of Helicobacter pylori. Antimicrob. Agents Chemother. 2000; 44: Ohara T, Goshi S, Taneike I, Tamura Y, Zhang HM, Yamamoto T. Inhibitory action of a novel proton pump inhibitor, rabeprazole, and its thioether derivative against the growth and motility of clarithromycin-resistant Helicobacter pylori. Helicobacter 2001; 6: Murakami K, Sato R, Okimoto T et al. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. Aliment. Pharmacol. Ther. 2003; 17: Isomoto H, Inoue K, Furusu H et al. High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillinmetronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. Aliment. Pharmacol. Ther. 2003; 18: Stack WA, Knifton A, Thirlwell D et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. Am. J. Gastroenterol. 1998; 93: Gisbert JP, Khorrami S, Calvet X, Pajares JM. Systematic review: rabeprazole-based therapies in Helicobacter pylori eradication. Aliment. Pharmacol. Ther. 2003; 17: Drossman DA, Richter JE, Talley NJ et al., eds. The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment, 1st edn. McLean, VA: Degnon Associates, Altman DG, Schulz KF, Moher D et al. The revised CONSORT statement for reporting randomized trials:
6 940 WM Wong et al. explanation and elaboration. Ann. Intern. Med. 2001; 134: Wong BCY, Wong WM, Wang WH et al. An evaluation of invasive and non-invasive tests for the diagnosis of Helicobacter pylori infection in Chinese: the best tests for routine clinical use and research purpose. Aliment. Pharmacol. Ther. 2001; 15: Wong WM, Wong BCY, Wong KW et al. 13 C-urea breath test with or without citric acid is equally accurate for the detection of Helicobacter pylori infection in Chinese. Aliment. Pharmacol. Ther. 2000; 14: Wong BCY, Wong WM, Yee YK et al. Rabeprazole based 3-day and 7-day triple therapy versus 7-day omeprazole based triple therapy for the treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 2001; 15: Ishizaki T, Horai Y. Cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment. Pharmacol. Ther. 1999; 13 (Suppl. 3): Lind T, Megraud F, Unge P et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: Goh KL, Rosaida MS, Salem O et al. Efficacy of a 1-week rabeprazole triple therapy for eradicating Helicobacter pylori and ulcer healing: an in-clincal-practice study. Chin. J. Dig. Dis. 2003; 4:
SUMMARY INTRODUCTION. Accepted for publication 25 May 2005
Aliment Pharmacol Ther 2005; 22: 243 249. doi: 10.1111/j.1365-2036.2005.02554.x Trends in the prevalence of peptic ulcer disease and Helicobacter pylori infection in family physician-referred uninvestigated
More informationThree-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study
Aliment Pharmacol Ther 2001; 15: 843±849. Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study B. C. Y. WONG*, W. H. WANG*, W.M.WONG*,G.K.K.LAU*,F.M.Y.FUNG*,N.N.S.KUNGà,
More informationCOMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION
Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,
More informationHelicobacter pylori Eradication Therapy Success Regarding Different Treatment Period Based on Clarithromycin or Metronidazole Triple-Therapy Regimens
Helicobacter ISSN 1523-5378 Filipec Blackwell Oxford, HEL 1083-4389 1523-5378 Journal XXX Original H. 2008 pylori Kanizaj compilation The UK Eradication Publishing Article Authors et al. Ltd 2008 Therapy
More informationHelicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.
An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology
More informationUrea Breath Test for Diagnosis of Helicobactor pylori. Original Policy Date 12:2013
MP 2.04.04 Urea Breath Test for Diagnosis of Helicobactor pylori Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date 12:2013 Return to Medical Policy Index
More informationHelicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W.
UvA-DARE (Digital Academic Repository) Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. Link to publication Citation for published
More informationManagement of Dyspepsia
MPharm Programme Management of Dyspepsia Slide 1 of 28 Learning Objectives Understand the principles and wider implications underpinning evidence based therapeutics in the key clinical specialities Objectively
More informationHelicobacter pylori: Diagnosis, treatment and risks of untreated infection
Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Klaus Mönkemüller Department of Gastroenterology, Hepatology und Infectius Diseases Otto-von-Guericke University, Magdeburg bb
More informationMaastricht Ⅴ /Florence
2016 21 10 577 Maastricht Ⅴ /Florence 200001 2015 10 8 9 Maastricht V 1 / 2 3 4 / 5 Maastricht Ⅴ Interpretation of Management of Helicobacter pylori Infection the Maastricht Ⅴ / Florence Consensus Report
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA o Patients of any age with ALARM signs should be referred through the 2-week referral system o Routine endoscopic investigation
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationOriginal Policy Date
MP 2.04.38 Genetic Testing for Helicobacter pylori Treatment Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return
More informationPREVENTING ASPIRIN-RELATED ULCER COMPLICATIONS
PREVENTING ASPIRIN-RELATED ULCER COMPLICATIONS LANSOPRAZOLE FOR THE PREVENTION OF RECURRENCES OF ULCER COMPLICATIONS FROM LONG-TERM LOW-DOSE ASPIRIN USE KAM CHUEN LAI, M.R.C.P., SHIU KUM LAM, M.D., KENT
More informationDr. LEUNG Lok Hang, Will
Direct access endoscopy booking by family physicians: evaluating a new service model and clinical predictors of positive endoscopy findings at primary care setting Dr. LEUNG Lok Hang, Will Department of
More informationManagement of dyspepsia and of Helicobacter pylori infection
Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia
More informationHelicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationEradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin
CASE REPORT Eradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin Takahisa Furuta 1, Mitsushige Sugimoto 2, Mihoko Yamade
More informationTreating H. pylori in 2016
Treating H. pylori in 2016 William D. Chey, MD, FACG Professor of Medicine University of Michigan The Case: A 38 yo Russian man presents with recurrent epigastric pain which occurs after meals and sometimes
More informationTreatment of Helicobacter pylori in Patients With Duodenal Ulcer Hemorrhage A Long-Term Randomized, Controlled Study
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 95, No. 9, 2000 2000 by Am. Coll. of Gastroenterology ISSN 0002-9270/00/$20.00 Published by Elsevier Science Inc. PII S0002-9270(00)01041-8 Treatment of Helicobacter
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationWhat is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori?
What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori? Sequential Therapy Versus Standard Triple- Drug Therapy for Helicobacter pylori
More informationHelicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W.
UvA-DARE (Digital Academic Repository) Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. Link to publication Citation for published
More informationOne-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers
Aliment Pharmacol Ther 1997; 11: 89 93. One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers J. LABENZ*, J.-P. IDSTRO M, B. TILLENBURG*,
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationTRANSPARENCY COMMITTEE OPINION. 13 December 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 December 2006 HELIKIT 75 mg, powder for oral solution CIP : 343 132-1 Applicant : MAYOLY SPINDLER 13 Curea anhydrous
More informationEDUCATION PRACTICE. Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? Clinical Scenario.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1086 1090 EDUCATION PRACTICE Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? RICHARD J. SAAD* and WILLIAM D.
More informationSELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY
SELECTED ABSTRACTS A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY The authors of this article present a 4-quadrant matrix based on 2 key clinical parameters: risk for adverse gastrointestinal (GI)
More information헬리코박터파일로리감염에서고용량및다빈도덱스란소프라졸과아모시실린이중치료 : 단일군전향연구
Korean J Gastroenterol Vol. 70 No. 4, 176-180 https://doi.org/10.4166/kjg.2017.70.4.176 pissn 1598-9992 eissn 2233-6869 ORIGINAL ARTICLE 헬리코박터파일로리감염에서고용량및다빈도덱스란소프라졸과아모시실린이중치료 : 단일군전향연구 박혜윤, 강은정, 김동근, 김기주,
More informationStudy population The study population comprised hypothetical patients with gastric and duodenal ulcer.
Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan Ikeda S, Tamamuro T, Hamashima C, Asaka M Record Status This is a critical
More informationType of intervention Diagnosis. Economic study type Cost-effectiveness analysis.
Noninvasive tests as a substitute for histology in the diagnosis of Helicobacter pylori infection Hahn M, Fennerty M B, Corless C L, Magaret N, Lieberman D A, Faigel D O Record Status This is a critical
More informationLow Dose Furazolidone for Eradication of H- pylori Instead of Clarithromycin: A Clinical Trial
Global Journal of Health Science; Vol. 7, No. 1; 2015 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Low Dose Furazolidone for Eradication of H- pylori Instead of
More informationBleeds in Cardiovascular Disease
Preventing Gastrointestinal Bleeds in Cardiovascular Disease Patients t on Aspirin i Joel C. Marrs, Pharm.D., BCPS Clinical Assistant Professor OSU/OHSU College of Pharmacy Pharmacy Practice IX (PHAR 766)
More informationMANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: helicobacter_pylori_testing 01/01/2019 N/A 01/01/2020 01/01/2019 Policy Effective April 1, 2019 Description
More informationThe role of antisecretory drugs in the treatment of Helicobacter pylori infection
Aliment Pharmacol Ther 1997; 11 (Suppl. 1): 21 25. The role of antisecretory drugs in the treatment of Helicobacter pylori infection W. L. PETERSON Department of Internal Medicine, University of Texas
More informationPerspectives from Viet Nam
International Symposium I (Management of antibiotics-resistant Helicobacter pylori infection) Perspectives from Viet Nam Vu Van Khien 1,HoDangQuyDung 2, Tran Thanh Binh 2 1 Department of GI Endoscopy,
More informationProton Pump Inhibitors (PPIs) (Sherwood Employer Group)
Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf
More informationGASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA
GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA MANAGEMENT Dyspepsia refers to a spectrum of usually intermittent upper gastrointestinal symptoms, including epigastric pain and heartburn. For the majority
More informationComparison of the Accuracy of Two Commercial Rapid Urase Tests, CLOtest and Pronto Dry, in Detecting Helicobacter pylori Infection ABSTRACT
Original Article Rojborwonwitaya J, Vijitjunyakul N THAI J GASTROENTEROL 2005 Vol. 6 No. 2 May - Aug. 2005 55 Comparison of the Accuracy of Two Commercial Rapid Urase Tests, CLOtest and Pronto Dry, in
More information11/19/2012. Comparison between PPIs G CELL. Risk ratio (95% CI) Patient subgroup. gastrin. S-form of omeprazole. Acid sensitive. coated.
REGULATION OF GASTRIC ACID SECRETION Comparison between PPIs Omeprazole Lansoprazole Rabeprazole Pantoprazole Esomeprazole gastrin G CELL + Acid sensitive Yes T1/2 30-60 minutes Main elimination Enteric
More informationPeptic Ulcer Disease Update
Peptic Ulcer Disease Update Col Pat Storms RAM 2005 Disclosure Information 84th Annual AsMA Scientific Meeting Col Patrick Storms I have no financial relationships to disclose. I will discuss the following
More informationTreatment of Helicobacter pylori Infection
Treatment of Helicobacter pylori Infection Epidemiology of H. pylori infection (North America) Which are the high risk groups? Epidemiology of H. pylori infection (North America) Which are the high risk
More information헬리코박터제균요법에있어서 CYP2C19 유전형이판토프라졸과라베프라졸포함치료법에미치는영향. Introduction 울산대학교의과대학서울아산병원소화기내과
The Korean Journal of Helicobacter and Upper Gastrointestinal Research Vol. 8, No. 1, 15-19, July 2008 Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: Comparison between Pantoprazole
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): November 22, 2011 Most Recent Review Date (Revised): July 22, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
More informationHelicobacter Connections. Barry Marshall
Helicobacter Connections Barry Marshall The greatest obstacle to knowledge is not ignorance, it is the illusion of knowledge. Daniel Boorstein - Historian Peptic Ulcers Duodenal Ulcer (DU) Gastric Ulcer
More informationGilles Jequier. Commercial Director Organobalance, a Novozymes Company
"Latest clinical Evidences showing that a proprietary Lactobacillus reuteri Strain can reduce the Symptoms associated with a Helicobacter pylori Infection" Gilles Jequier Commercial Director Organobalance,
More informationDisclosures. Co-founder and Chief Science Officer, TechLab
H. pylori testing Disclosures Co-founder and Chief Science Officer, TechLab Learning Objectives Evaluate the appropriate testing methodology by balancing performance, economics, and workflow. Discuss the
More informationI. Kalfus MD, D. Riff MD, R. Fathi PhD, D. Graham MD
A Randomized Double Blind Placebo Controlled Phase III Study to Assess the Safety and Efficacy of Rifabutin Triple Therapy (RHB-105) for Helicobacter pylori (H. pylori) Infection in Dyspepsia Patients
More informationDrug Class Monograph
Drug Class Monograph Class: Proton Pump Inhibitors Drugs: Aciphex Sprinkle (rabeprazole), Dexilant (dexlansoprazole), Lansoprazole, Nexium (esomeprazole capsule, esomeprazole granules), Omeprazole, Pantoprazole,
More informationinstrument. When 13C-UBT positive value is greater than or equal to / - 0.4, the the subject can be 1. Data and methods details are as follows:
Application of 13 C-urea breath test in screening helicobacter pylori infection during health examination in Chengdu, Sichuan YANG Yan-hua. LIU Yu-ping. CHENG You-fu, SHUAI Ping. LU Qiao. ZHENG Xiao-xia,
More informationEvaluation of a new rapid immunoassay for the detection of Helicobacter pylori in faeces: a prospective pilot study
Aliment Pharmacol Ther 2005; 21: 485 489. doi: 10.1111/j.1365-2036.2005.02355.x Evaluation of a new rapid immunoassay for the detection of Helicobacter pylori in faeces: a prospective pilot study L. TREVISANI*,
More informationTreatment of H. pylori Infection: The Reality
YALE JOURNAL OF BIOLOGY AND MEDICINE 71 (1998), pp. 119-124. Copyright 1999. All rights reserved. Treatment of H. pylori Infection: The Reality Nimish Vakil University of Wisconsin Medical School, Milwaukee
More informationPharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W
Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W Record Status This is a critical abstract of an economic evaluation that
More informationYang K. Chen, MD* Prahalad Jajodia, MD Lino DeGuzman, MD Shahid A. Khan, MD Vaman S. Jakribettuu, MD*
Randomized Controlled Trial Comparing Proton Pump Inhibitor- Based Eradication Regimen versus Low-Cost Eradication Regimen for Patients with Helicobacter pylori with Uninvestigated Dyspepsia Yang K. Chen,
More informationAssessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer
618 University Department of Medicine and Therapeutics, Western Infirmary, Glasgow G11 6NT, UK K E L McColl A El-Nujumi L S Murray E M El-Omar A Dickson A W Kelman T E Hilditch Correspondence to: Professor
More informationCHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)?
CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? A. Chronic alcohol ingestion B. Nonsteroidal antiinflammatory
More informationTECHNOLOGY OVERVIEW: PHARMACEUTICALS
TECHNOLOGY OVERVIEW: PHARMACEUTICALS ISSUE 3.1 JUNE 1996 PHARMACEUTICAL MANAGEMENT OF PEPTIC ULCER DISEASE prepared by Ms. Christine Perras, BSc Phm Pharmaceutical Associate, CCOHTA and Dr. Nicolaas Otten,
More informationPEPTIC ULCER DISEASE JOHN R SALTZMAN, MD. Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School
PEPTIC ULCER DISEASE JOHN R SALTZMAN, MD Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School No disclosures Disclosures Overview Causes of peptic ulcer disease
More informationAmerican College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection
American Journal of Gastroenterology ISSN 0002-9270 C 2007 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2007.01393.x Published by Blackwell Publishing American College of Gastroenterology
More informationSetting The setting was primary care. The economic study was conducted in Canada.
Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment - Helicobacter pylori positive (CADET-Hp) randomised controlled
More informationEfficacy and Tolerability of a Third-Line, Levofloxacin-Based, 10-Day Sequential Therapy in Curing Resistant Helicobacter Pylori Infection
ORIGInAL PAPERs Efficacy and Tolerability of a Third-Line, Levofloxacin-Based, 10-Day Sequential Therapy in Curing Resistant Helicobacter Pylori Infection Antonio Tursi 1, Marcello Picchio 2, Walter Elisei
More informationQUICK QUERIES. Topical Questions, Sound Answers
QUICK QUERIES Topical Questions, Sound Answers Dyspepsia: An Evidence-Based Approach Alan B. R. Thomson, MD, PhD, FRCPC, FACP, FACG Presented at the University of Alberta s Medical Grand Rounds, University
More informationA Heaney, J S A Collins, RGPWatson, R J McFarland, K B Bamford, T C K Tham
186 Royal Victoria Hospital, Belfast, A Heaney J S A Collins Department of Medicine, Queen s University, Belfast, RGPWatson Ulster Hospital, Dundonald, R J McFarland T C K Tham Department of Microbiology
More informationCommittee Approval Date: October 14, 2014 Next Review Date: October 2015
Medication Policy Manual Topic: esomeprazole-containing medications: - Nexium - Vimovo - esomeprazole strontium Policy No: dru039 Date of Origin: May 2001 Committee Approval Date: October 14, 2014 Next
More informationDisclosures. GI Motility Disorders. Gastrointestinal Motility Disorders & Irritable Bowel Syndrome
Gastrointestinal Motility Disorders & Irritable Bowel Syndrome None Disclosures Jasmine Zia, MD Acting Assistant Professor Division of Gastroenterology, University of Washington 6 th Asian Health Symposium
More informationThe usual dose is 40 mg daily with amoxycillin 1.5 g (750 mg b.d.) for 2 weeks. Up to 2 g/day of amoxycillin has been used in clinical trials.
Name Gasec - 2 Gastrocaps Composition Gasec-20 Gastrocaps Each Gastrocaps contains: Omeprazole 20 mg (in the form of enteric-coated pellets) Properties, effects Proton Pump Inhibitor Omeprazole belongs
More informationORIGINAL INVESTIGATION. Maintenance Treatment Is Not Necessary After Helicobacter pylori Eradication and Healing of Bleeding Peptic Ulcer
ORIGINAL INVESTIGATION Maintenance Treatment Is Not Necessary After Helicobacter pylori Eradication and Healing of Bleeding Peptic Ulcer A 5-Year Prospective, Randomized, Controlled Study Chen-Chiung Liu,
More informationACG Clinical Guideline: Treatment of Helicobacter pylori Infection
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection William D. Chey, MD, FACG 1, Grigorios I. Leontiadis, MD, PhD 2, Colin W. Howden, MD, FACG 3 and Steven F. Moss, MD, FACG 4 1 Division
More informationSecond Asia Pacific Consensus Guidelines for Helicobacter pylori infection
doi:10.1111/j.1440-1746.2009.05982.x SPECIAL ARTICLE jgh_5982 1587..1600 Second Asia Pacific Consensus Guidelines for Helicobacter pylori infection K Ming Fock,* Peter Katelaris, Kentaro Sugano, Tiing
More informationHelicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師
Helicobacter pylori 幽門螺旋桿菌 馬偕紀念醫院新竹分院一般內科, 肝膽腸胃科陳重助醫師 Hp : Helicobacter pylori Part 1. Pathophysiology and immune response Pathogenesis of Hp infection Part 2. Clinical manifestation Part 3. Dx tests for
More informationThe long-term management of patients with bleeding duodenal ulcers
Aliment Pharmacol Ther (1997); 11: 505±510. The long-term management of patients with bleeding duodenal ulcers M. E. MCALINDON, J. S. W. TAYLOR & S. D. RYDER Department of Medicine, University Hospital,
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:10.22034/APJCP.2017.18.4.927 Outcomes of a Randomized Controlled Trial Comparing Modified High Dose Omeprazole RESEARCH ARTICLE Outcomes of a Randomized Controlled Trial Comparing Modified High Dose
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Adherence, to bismuth quadruple therapy, 543 546 Adjuvant therapy, probiotics as, 567 569 Age factors, in gastric cancer, 611 612, 616 AID protein,
More informationClinical Study Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection
BioMed Research International Volume 2015, Article ID 163960, 6 pages http://dx.doi.org/10.1155/2015/163960 Clinical Study Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter
More informationORIGINAL INVESTIGATION. Effectiveness of Helicobacter pylori Therapies in a Clinical Practice Setting
ORIGINAL INVESTIGATION Effectiveness of Helicobacter pylori Therapies in a Clinical Practice Setting M. Brian Fennerty, MD; David A. Lieberman, MD; Nimish Vakil, MD; Nathan Magaret; Douglas O. Faigel,
More informationArab Journal of Gastroenterology
Arab Journal of Gastroenterology 14 (2013) 1 5 Contents lists available at SciVerse ScienceDirect Arab Journal of Gastroenterology journal homepage: www.elsevier.com/locate/ajg Original Article Penbactam
More informationResearch Article Performance of Routine Helicobacter pylori Invasive Tests in Patients with Dyspepsia
Gastroenterology Research and Practice Volume 2013, Article ID 184806, 5 pages http://dx.doi.org/10.1155/2013/184806 Research Article Performance of Routine Helicobacter pylori Invasive Tests in Patients
More informationTitle. Author(s)Kato, Mototsugu. Issue Date Doc URL. Type. Note. File Information.
Title Effects of lansoprazole plus amoxycillin on the cure Author(s)Kato, Mototsugu Issue Date 1996-12-25 Doc URL http://hdl.handle.net/2115/32629 Type theses (doctoral) Note 共著者あり 共著者名 :Asaka Masahiro,
More information6/25/ % 20% 50% 19% Functional Dyspepsia Peptic Ulcer GERD Cancer Other
Peptic Ulcer Disease and Dyspepsia John M. Inadomi, MD Professor of Medicine UCSF Chief, Clinical Gastroenterology San Francisco General Hospital Case History 49 y/o woman complains of several months of
More informationUpdates in Evaluation and Management of Dyspepsia and H. Pylori Infection
Updates in Evaluation and Management of Dyspepsia and H. Pylori Infection Isabel Lee, MD Associate Professor of Health Sciences UCSF Department of Family and Community Medicine Disclosures None 2 Session
More informationSuccess Rate of Furazolidone Based Triple Therapy for Eradication of Helicobacter Pylori in Children
Original Article Iran J Pediatr Sep 2008; Vol 19 (No 3), Pp:244-248 Success Rate of Furazolidone Based Triple Therapy for Eradication of Helicobacter Pylori in Children Mehri Najafi, MD* 1 ; Ahmad Khodadad,
More informationRpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives
Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment
More informationOriginal article J Bas Res Med Sci 2015; 2(4):45-50.
Comparison between the effectiveness of Furazolidone and Clarithromycin on eradication of helicobacter pylori among patients with peptic ulcer Asghar Rahmani 1, Ali Jafari Haidarloo 2, Hoda Mabrokzadeh
More informationClinical Policy Title: Noninvasive testing for H. pylori
Clinical Policy Title: Noninvasive testing for H. pylori Clinical Policy Number: 08.01.04 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: August 17, 2016 Next
More informationOutline. Definition (s) Epidemiology Pathophysiology Management With an emphasis on recent developments
Chronic Dyspepsia Eamonn M M Quigley MD FRCP FACP MACG FRCPI Lynda K and David M Underwood Center for Digestive Disorders Houston Methodist Hospital Houston, Texas Outline Definition (s) Epidemiology Pathophysiology
More informationHelicobacter pyloni and upper gastrointestinal
314 Helicobacter pyloni and upper gastrointestinal disease: a survey of gastroenterologists in the United Kingdom Gut 1995; 37: 314-318 R Milne, R P H Logan, D Harwood, J J Misiewicz, D Forman Health Services
More informationGastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D
Gastro-oesophageal reflux disease and peptic ulcer disease By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D Gastro-oesophageal reflux disease and peptic ulcer disease Learning objectives:
More informationOne-third of adults experience pain or discomfort in
GASTROENTEROLOGY 2002;122:1270 1285 Dyspepsia Management in Primary Care: A Decision Analysis of Competing Strategies BRENNAN M. R. SPIEGEL,* NIMISH B. VAKIL, and JOSHUA J. OFMAN*, *Department of Medicine
More informationPRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW
PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY Dyspepsia refers to a broad range of symptoms related
More informationProton pump inhibitor (proton pump inhibitor)-based triple therapies using clarithromycin in combination SUMMARY INTRODUCTION
Aliment Pharmacol Ther 2003; 18: 799 804. doi: 10.1046/j.1365-2036.2003.01764.x Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter
More informationClinical Policy Title: Noninvasive testing for H. pylori
Clinical Policy Title: Noninvasive testing for H. pylori Clinical Policy Number: 08.01.04 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: August 17, 2016 Next
More informationOmeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty.
Omeprazole 10mg Name, Restriction, Manner of administration and form omeprazole 10 mg enteric tablet, 30 (8332M) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form omeprazole
More informationFunctional Dyspepsia
Functional Dyspepsia American College of Gastroenterology Boston Massachusetts, June 2015 Brian E. Lacy, PhD, MD, FACG Professor of Medicine Geisel School of Medicine at Dartmouth Chief, Section of Gastroenterology
More informationThe significance of Helicobacter pylori in the approach of dyspepsia in primary care Arents, Nicolaas Lodevikus Augustinus
University of Groningen The significance of Helicobacter pylori in the approach of dyspepsia in primary care Arents, Nicolaas Lodevikus Augustinus IMPORTANT NOTE: You are advised to consult the publisher's
More informationPeptic ulcer disease Disorders of the esophagus
Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Burning epigastric pain Exacerbated by fasting Improved with meals Ulcer: disruption of mucosal integrity >5 mm in size, with depth
More informationSetting The setting was community. The economic study was carried out in the USA.
Costs of managing Helicobacter pylori-infected ulcer patients after initial therapy Griffiths R I, Rabeneck L, Guzman G, Cromwell D M, Strauss M J, Robinson J W, Winston B, Li T, Graham D Y Record Status
More informationClinical Policy Title: Noninvasive testing for H. pylori
Clinical Policy Title: Noninvasive testing for H. pylori Clinical Policy Number: 08.01.05 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: August 17, 2017 Next
More information